Monoclonal gammopathy and neuropathy.
There is a known coexistence between polyneuropathy and monoclonal gammopathy (immunoglobulin M, immunoglobulin G, immunoglobulin A). Antibodies to several glycoconjugates of the peripheral nervous system have been found in 50-65% of patients with immunoglobulin M monoclonal proteins, and distinct clinical syndromes have been recognized. However, if no antibodies are found, a relationship between monoclonal protein and polyneuropathy is still debatable. Therapeutic intervention is generally directed at removing the autoantibodies by reducing the number of monoclonal B-cells.
Notermans
N C
NC
Department of Neuromuscular Disorders, University Hospital Utrecht, The Netherlands.
D000368:Aged; D001323:Autoantibodies / Q000276:immunology; D064211:Connectin; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D007075:Immunoglobulin M / Q000276:immunology; D008998:Monoclonal Gammopathy of Undetermined Significance / Q000150:complications*; D009124:Muscle Proteins; D009194:Myeloma Proteins / Q000276:immunology; D010523:Peripheral Nervous System Diseases / Q000276:immunology* / Q000628:therapy
D001323:Autoantibodies; D064211:Connectin; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D009124:Muscle Proteins; D009194:Myeloma Proteins; C085016:multiple myeloma M-proteins